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Urinary albumin excretion is a powerful predictor of
progressive cardiovascular and renal disease. In rats and
humans, administration of a synthetic vasopressin analogue,
1-desamino-8-D-arginine-vasopressin, increases urinary
albumin excretion; however, it is unknown if endogenous
vasopressin levels influence albumin excretion. To determine
this we measured copeptin, a marker of endogenous
vasopressin levels, and its association with urinary albumin
excretion in 7593 patients in the PREVEND study, a
prospective population based, observational cohort. Urinary
albumin excretion was measured in two consecutive 24-h
urine samples by nephelometry while copeptin was
measured by an immunoassay. Median copeptin
concentrations were significantly higher in males than
females and high levels were associated with significantly
lower 24-h urine volumes of high osmolarity. With increasing
quintiles of copeptin levels, the percentage of
microalbuminuric subjects increased from 13 to 25 for males
and from 8 to15 for females. This association was
independent of age and other potential confounders;
however, we found an interaction between age and copeptin
in their association with urinary albumin excretion. Our study
shows that plasma copeptin levels are associated with
microalbuminuria, consistent with the hypothesis that
vasopressin is involved in urinary albumin excretion. If future
studies show that this association is causal, then drinking
more water or pharmacological intervention to decrease
plasma vasopressin may have beneficial effects on the
kidney, especially in the elderly.
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Urinary albumin excretion (UAE) is a powerful predictor of
cardiovascular mortality and progressive renal function
deterioration, not only in diabetics, but also in the general
population.1,2 It is assumed that UAE not only reflects
glomerular damage, but is also related to systemic endothelial
dysfunction. Lowering albuminuria is associated with better
renal3 and cardiovascular4 outcome. Identifying modifiable
factors that cause increase in UAE is, therefore, important,
since intervention directed to these factors might be expected
to result in better renal and cardiovascular prognosis.
Vasopressin has been hypothesized as one of these
modifiable factors. Vasopressin is also known as antidiuretic
hormone since it binds to the V2 receptors in the collecting
ducts, inducing the insertion of the molecular water channel
aquaporin-2 in the luminal membrane of principal cells. This
mediates water reabsorption, thereby reducing water excre-
tion.5 Despite its importance for normal water regulation in
the body, vasopressin also has been reported to exert
deleterious effects on the kidney. Administration of
1-desamino-8-D-arginine vasopressin (a vasopressin-receptor
agonist) to rats and humans induces albuminuria6,7 and
inhibition of vasopressin by drinking water or V2 antagonism
reduces proteinuria in rats with renal failure8,9 and
diabetes.10
Interest in pleiotropic effects of vasopressin has risen
because vasopressin antagonists are expected to become
available for clinical use within the next years. Human studies
investigating the influences of endogenous vasopressin on
albuminuria are, however, lacking. Presumably this is due to
the fact that direct measurement of vasopressin in humans is
problematic. More than 90% of vasopressin in the circulation
is bound to platelets;11 vasopressin is unstable in isolated
plasma11 and most vasopressin assays have relatively limited
sensitivity. Recently, an assay has been developed to measure
copeptin, the C-terminal portion of the precursor of
vasopressin. Copeptin has been proven to be a reliable
marker of vasopressin secretion and a useful substitute for
circulating vasopressin concentration in clinical routine.12,13
These characteristics make copeptin a promising marker,
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which allows for the first time (indirect) measurement of
vasopressin in epidemiological studies.
Given the aforementioned, we hypothesized that in the
general population copeptin (a surrogate marker of vaso-
pressin) is associated with albuminuria, and investigated this
in an observational, cross-sectional study.
RESULTS
Characteristics of participating subjects are presented for
quintiles of copeptin in Table 1 separately for gender. A total
of 7,593 subjects (47.2% male, aged 49±13 years) were
analyzed. Median copeptin concentration in these subjects
was 4.7 pmol/l (2.9–7.5), with significantly higher concentra-
tion in males (6.2 pmol/l(4.1–9.5)) than in females (3.6 pmol/l
(2.4–5.5), Po0.001). Table 2 depicts the associations between
copeptin and these variables for males and females. As
copeptin concentration is significantly associated with age, an
additional column is included to represent the association
adjusted for age. When adjusted for age, copeptin concentra-
tion was positively associated with serum creatinine, blood
pressure, body mass index (BMI), and sodium intake levels in
males and females, whereas the association with estimated
glomerular filtration rate (eGFR) was negative. Associations
between copeptin and smoking and use of angiotensin-
converting enzyme inhibitors/angiotensin-II-receptor block-
ers (ACEi/ARBs) are significant in females and not in males,
while plasma glucose and plasma cholesterol levels are
significant in males but not in females. The association
between copeptin level and blood pressure is presented in the
table for the whole group. For subjects on antihypertensive
medication (males n¼ 494, females n¼ 510) this association
is not significant. For those who do not receive antihyper-
tensive treatment, the associations between copeptin and
blood pressure are approximately similar to that of the whole
group (depicted in Table 2).
To investigate whether vasopressin concentration is
consistent with normal physiology, we tested the associations
between copeptin and 24-h urinary volume and 24-h urinary
osmolarity. A high concentration of copeptin was associated
with low 24-h urinary volume (in males R¼0.27 and in
females R¼0.23, both Po0.001) and high urinary
osmolarity (in males R¼ 0.27 and in females R¼ 0.23, both
Po0.001). The correlation of copeptin with overall calcu-
lated urinary osmolarity was stronger than that with the
single determinants of the calculated osmolarity (for
copeptin and urinary sodium concentration R-value was
Table 1 | Characteristics of participating subjects (n=7593) per quintile of copeptin for males (M) and females (F)
Quintile 1 2 3 4 5
Copeptin (pmol/l) M 0.6–3.7 3.8–5.3 5.4–7.3 7.4–10.4 10.5–632
F 0.1–2.1 2.2–3.0 3.1–4.2 4.3–6.2 6.3–131
n M 730 726 696 716 715
F 772 829 809 803 797
Age (years) M 49±13 48±13 50±13 49±12 52±13
F 47±12 47±12 48±12 48±12 50±12
History of CHD (n) (%) M 58 (8) 43 (6) 55 (8) 63 (9) 69 (10)
F 21 (3) 15 (2) 20 (3) 21 (3) 25 (3)
Smoking (n) (%) M 113 (15) 123 (17) 118 (17) 126 (18) 95 (13)
F 98 (13) 94 (11) 136 (17) 157 (20) 165 (21)
BMI (kg/m2) M 25.7±3.3 25.9±3.3 26.4±3.6 26.5±3.7 26.7±4.0
F 25.4±4.1 25.6±4.5 25.8±4.7 26.3±4.9 26.2±5.4
MAP (mmHg) M 93.4±11.3 94.3±10.5 95.2±11.6 95.6±11.1 98.5±12.3
F 87.9±11.8 88.5±11.8 88.2±11.4 88.9±12.4 90.0±12.6
Use of diuretics (n) (%) M 19 (3) 21 (3) 21 (3) 20 (3) 39 (5)
F 40 (5) 39 (5) 28 (3) 42 (5) 48 (6)
Use of ACEi/ARB (n) (%) M 42 (6) 35 (5) 34 (5) 33 (5) 52 (7)
F 27 (3) 28 (3) 22 (3) 34 (4) 44 (6)
Sodium intake (mmol/day) M 154±51 161±53 163±54 163±57 156±54
F 123±42 126±41 127±42 125±42 127±47
Plasma glucose (mmol/l) M 4.9±0.9 4.9±0.9 4.9±0.9 5.1±1.3 5.3±1.8
F 4.7±0.8 4.8±1.3 4.7±0.9 4.7±0.9 4.8±1.3
Diabetes (n) (%) M 26 (4) 26 (4) 18 (3) 26 (4) 50 (7)
F 18 (2) 28 (4) 23 (3) 18 (2) 28 (4)
Plasma cholesterol (mmol/l) M 5.6±1.1 5.6±1.1 5.6±1.1 5.7±1.1 5.8±1.2
F 5.6±1.2 5.5±1.1 5.6±1.2 5.6±1.1 5.8±1.2
Serum CRP (mg/l) M 1.0 (0.5–2.3) 1.0 (0.5–2.4) 1.2 (0.6–2.7) 1.3 (0.6–3.0) 1.4 (0.7–3.0)
F 1.2 (0.5–3.2) 1.2 (0.5–3.0) 1.4 (0.6–3.2) 1.4 (0.6–3.3) 1.5 (0.6–3.6)
Serum creatinine (mmol/l) M 89±11 90±13 91±13 92±13 98±41
F 74±9 75±10 76±10 77±10 78±17
eGFR (MDRD) (ml/min 1.73m2) M 87±14 86±15 84±14 83±14 80±16
F 80±13 79±13 78±13 77±13 75±15
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II-receptor blocker; BMI, body mass index; CHD, coronary heart disease; CRP, C-reactive protein;
eGFR, estimated glomerular filtration rate; MAP, mean arterial pressure; MDRD, modification of diet in renal disease.
Parametric variables are expressed as mean±s.d., whereas non-parametric variables are expressed as median (interquartile range).
Variables are presented as mean±s.d. or median (IQR) for M (males) and F (females) separately.
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0.25 for males and 0.22 in females; for urinary potassium
concentration this was 0.16 for males and 0.15 for females;
and for urinary urea concentration, R-value was 0.25 and
0.21, respectively). The associations of copeptin with 24-h
urinary volume and 24-h urinary osmolarity are presented in
Figure 1. Twenty-four-hour urinary volume is highest in
quintile-1 and lowest in quintile-5 (1.74±0.51 versus
1.36±0.44 l for males and 1.82±0.60 versus 1.43±0.52 l
for females), whereas urinary osmolarity varies an opposite
manner (533±155 versus 667±183mOsm/l for males and
418±133 versus 530±170mOsm/l for females). The osmo-
lar load is not different between quintile-1 and quintile-5 for
each gender (for males 876mOsm in quintile 1 versus
841Osm in quintle-5, P¼ 0.06; and for females 707 versus
698mOsm, P¼ 0.3).
Median UAE for the whole group was 9.3mg/24 h
(6.4–16.8) and 986 (13%) of the subjects had micro-
albuminuria (microalbuminuria is defined as UAE X30mg/
24 h). Copeptin level was significantly associated with UAE
(R¼ 0.20, Po0.001). This association is depicted in Figure 2.
UAE is higher in the quintile with higher copeptin values:
quintile-1: 9.4mg/24 h (6.5–17.2) for males and 7.3mg/24 h
(5.5–11.7) for females, and quintile-5: 13.4mg/24 h (8.1–29.8)
for males and 10.0mg/24 h (6.6–18.3) for females. Also
depicted in Figure 2 is the percentage of microalbuminuric
subjects per quintile of copeptin. The percentage of micro-
albuminuric subjects is highest in the highest quintile of
copeptin.
In Figure 3 the association between copeptin and UAE is
shown in addition to that of modifiable factors that
are known to influence UAE (mean arterial pressure
(MAP), BMI, fasting plasma glucose, and cholesterol). For
this purpose gender-stratified quintiles were made for
every factor specifically. This figure shows that the association
between MAP and UAE is the strongest and that
the association between copeptin and UAE is comparable
to that between glucose, BMI or cholesterol, and UAE.
R-values for the association between MAP, glucose, BMI, and
cholesterol versus UAE are respectively 0.36, 0.25, 0.21
and 0.12.
The association between copeptin and UAE was also
investigated using copeptin as a continuous variable in
multivariate regression analyses. We adjusted this association
in a multivariate model for several potential confounders.
Despite the fact that our regression model did not show
indications for an interaction with gender and that the
regression coefficients for males and females were not
different (P¼ 0.11 for the crude model and 0.37 for the
fully adjusted model), results are depicted for males and
females separately in Table 3. The association was significant
with a b-value of 0.25 for males and 0.19 for females, both
Po 0.001 (Table 3, model 1). Adjusted for gender, the
association remained significant. Further adjustment for
Table 2 | Associations between copeptin and other variables
for males and females
Males Females
Crude Age-adjusted Crude Age-adjusted
Variable St. b P St. b P St. b P St. b P
Age 0.07o0.001 — — 0.09o0.001 — —
History of CHD 0.02 0.32 0.01 0.79 0.02 0.19 0.01 0.67
Smoking 0.02 0.34 0.01 0.51 0.12o0.001 0.13o0.001
BMI 0.09o0.001 0.07o0.001 0.06o0.001 0.04 0.03
MAP 0.15o0.001 0.15o0.001 0.05o0.001 0.01 0.48
Use of diuretics 0.05 0.002 0.04 0.03 0.04 0.021 0.02 0.32
Use of ACEi/ARB 0.02 0.24 0.03 0.07 0.05 0.001 0.05 0.002
Sodium intake 0.03 0.12 0.03 0.041 0.03 0.10 0.04 0.019
Plasma glucose 0.10o0.001 0.0 o0.001 0.03 0.03 0.01 0.69
Diabetes 0.07 0.001 0.05 0.006 0.02 0.24 0.00 0.85
Plasma cholesterol 0.07o0.001 0.06o0.001 0.06o0.001 0.03 0.14
Serum CRP 0.05 0.002 0.04 0.015 0.04 0.03 0.03 0.06
Serum creatinine 0.18o0.001 0.18o0.001 0.18o0.001 0.17o0.001
eGFR 0.17o0.001 0.18o0.001 0.15o0.001 0.13o0.001
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II-receptor blocker;
BMI, body mass index; CHD, coronary heart disease; CRP, C-reactive protein;
eGFR, estimated glomerular filtration rate; MAP, mean arterial pressure.
Because age was significantly associated with copeptin levels, coefficients are also
depicted adjusted for age. Log copeptin concentration was entered as the
dependent variable.
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Figure 1 |Associations between quintiles of copeptin and 24-h
urinary volume (upper panel) and 24-h urinary osmolarity
(lower panel) for males and females. Depicted are mean values
(±95% confidence interval of the mean). Differences between the
quintiles were tested by analysis of variance.
Kidney International (2010) 77, 29–36 31
E Meijer et al.: Copeptin and albuminuria o r ig ina l a r t i c l e
potential cardiovascular confounders (model 3) and
medication that could potentially influence both vasopressin
(and thus copeptin concentration) and UAE (model 4),
did not materially influence the association between
copeptin and UAE.
Urinary osmolarity was also associated with UAE with a
standardized b-value of 0.05 for males and 0.07 for females,
both Po0.001. This association was independent of age,
gender, potential cardiovascular confounders, and use of
diuretics and/or ACEi/ARBs.
In the crude and the full corrected model, an interaction
was found between age and log copeptin concentration on
UAE (Po0.001). In Figure 4, the association between
copeptin and UAE is depicted stratified for quintiles of age.
Copeptin was associated with UAE in all age groups, but this
association is the strongest when subjects are older. In the
youngest age quintile (age 28–36 years), copeptin concentra-
tion rose from 1.9 pmol/l (1.6–2.7) to 11.2 pmol/l (8.3–14.4)
from the first to the fifth quintile of copeptin, with median
UAE rising from 7.5mg/24 h (5.8–10.4) to 8.5mg/24 h
(6.2–13.6). In the oldest age quintile of our study (age
62–75 years), copeptin concentration rose from 2.0mg/24 h
(1.5–2.8) to 11.9mg/24 h (9.3–15.8) while median UAE rose
from 11.1mg/24 h (7.0–23.5) to 18.2mg/24 h (9.4–40.8).
Twenty-four-hour urinary volume and 24-h urinary osmo-
larity were significantly different, with 24-h urinary volume
being higher and 24-h urinary osmolarity being lower in the
oldest age group when compared with the youngest age
group (in the highest quintile of copeptin, 1,434±465ml
and 543±163mOsm/l for the oldest quintile versus
1259±485ml and 673±202mOsm/l in the youngest
quintile).
Of note, apart from the interaction of age and log
copeptin concentration on UAE, we did not find any other
interactions between baseline characteristics and log copeptin
concentration on UAE. The results we obtained in the various
sensitivity analyses (stratified for ACEi/ARB and diuretics use
(yes/no), with or without outliers of copeptin, with or
without diabetic subjects, and without subjects with non-
fasting blood sample and without subjects with 420%
difference in creatinine excretion in two consecutive 24-h
urine collections and repeated with IDMS-traceable creati-
nine levels), were essentially similar to those from our
primary analyses.
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Figure 2 |Association between quintiles of copeptin and
median 24-h UAE (upper panel) and prevalence of micro-
albuminuria (lower panel) for males and females. Differences
between the quintiles were tested by Kruskal–Wallis test.
UAE, urinary albumin excretion.
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panel) and copeptin and microalbuminuria (lower panel)
compared with known modifiable factors influencing UAE.
Depicted are gender-stratified quintiles of copeptin
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DISCUSSION
In this study, we found copeptin levels to be higher in males
than females, corresponding with lower urine volumes and
higher urinary osmolarity in males versus females. In both
males and females, high copeptin concentration (a surrogate
for vasopressin) is associated with low 24-h urinary volume
and high 24-h urinary osmolarity. Furthermore, our study
shows that copeptin is associated with UAE: higher the
copeptin level, higher the UAE and the more micro-
albuminuric the subjects, again, both in males and in
females. This association remained significant after adjust-
ment for age, potential cardiovascular confounders, and
medication that could potentially influence both vasopressin
(and thus copeptin) secretion and UAE. The association
between copeptin and UAE was found to be most
pronounced for older subjects. The observed association
between vasopressin and UAE is consistent with our
hypothesis that vasopressin induces albuminuria.
Animal studies showed that administration of 1-desamino-
8-D-arginine-vasopressin (a V2-receptor agonist) induced
an increase in urinary protein excretion and a more rapid
decline of renal function.14 Also in humans, short-term
1-desamino-8-D-arginine-vasopressin administration has been
shown to result in an increase in UAE.6 In contrast, vasopressin
inhibition by drinking water8 or by V2 antagonism15 led to a
decrease in proteinuria in rats with renal failure. In a rat model
of diabetes mellitus, chronic treatment with a vasopressin V2
antagonist prevented the rise in albuminuria seen in untreated
rats.10 In these untreated rats with diabetes mellitus, albumi-
nuria was significantly correlated with free-water reabsorption,
suggesting an association between albuminuria and vasopressin.
The unfavorable renal effects of vasopressin have been
argued to be partly due to an effect on blood pressure.
Vasopressin may contribute to hypertension either through a
direct effect on vascular smooth muscle through activation of
the V1a receptor,16 or by V2-receptor-dependent tubular
effects. The latter includes enhancement of sodium reabsorp-
tion in the collecting duct17 and increase in intrarenal urea
recycling, which participates in the urine-concentrating
mechanism. The latter may indirectly modify NaCl concen-
tration at the macula densa, thereby influencing tubuloglo-
merular feedback, leading to renin release, hypertension,
glomerular hyperfiltration, and proteinuria.18,6 In our study,
however, the association between copeptin and UAE was
independent of systemic blood pressure, indicating that other
mechanisms of action may be important. Furthermore,
urinary osmolarity was independently associated with UAE,
but less strong than the association between copeptin and
UAE, suggesting that besides the antidiuretic effect of
vasopressin, other effects (e.g., pressor effects) may also be
involved in the relationship of copeptin with UAE.
Induction of specific glomerular hyperfiltration or decre-
ased tubular albumin reabsorption might be mechanisms
underlying this relationship.
We also found copeptin to be associated with renal
function. Subjects with higher levels of copeptin had lower
renal function. Reasons for this phenomenon could be that
copeptin causes renal function decline or that subjects with
low renal function are less sensitive to the actions of copeptin/
vasopressin. The fact that copeptin is partly cleared by the
kidney19 is not a likely explanation, because negative feedback
loops will downregulate copeptin/vasopressin secretion.
Table 3 | Associations between log copeptin concentration and log UAE in univariate (model 1) and multivariate models
Model Corrected for b 95% CI for b P
Males
1  (Crude) 0.25 0.20–0.30 o0.001
2 As 1+age 0.21 0.16–0.26 o0.001
3 As 2+MAP, BMI, smoking, glucose, cholesterol, CRP, and eGFR 0.10 0.05–0.16 o0.001
4 As 3+diuretics and ACEi/ARB. 0.09 0.04–0.15 0.001
Females
1  (Crude) 0.19 0.15–0.23 o0.001
2 As 1+age 0.17 0.14–0.22 o0.001
3 As 2+MAP, BMI, smoking, glucose, cholesterol, CRP, and eGFR 0.16 0.11–0.21 o0.001
4 As 3+diuretics and ACEi/ARB. 0.17 0.12–0.21 o0.001
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II-receptor blocker; BMI, body mass index; CHD, coronary heart disease; CI, confidence interval; CRP,
C-reactive protein; eGFR, estimated glomerular filtration rate; MAP, mean arterial pressure.
Log copeptin concentration was entered in the regression analyses as independent and log UAE as the dependent variable.
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We investigated potential interactions between log copep-
tin concentration on the one hand and gender, age, and
baseline renal function on the other hand, because we wanted
to investigate whether there are certain subgroups of subjects
that are more susceptible to copeptin’s influences. We found
no interaction between copeptin and gender or renal
function, suggesting that the association between log
copeptin concentration and UAE is essentially similar in
men and women, and independent of renal function. The
interaction between age and copeptin was, however, sig-
nificant, suggesting that the association between log copeptin
concentration and UAE is most pronounced in older subjects
(Figure 4). This could be explained because they might be
more vulnerable to the influence of vasopressin or because
they have been longer exposed to high vasopressin levels.
Another explanation for this interaction could be that older
subjects might have decreased tubular reabsorption. This
could result in both increased UAE and decreased concentra-
tion capacity (24-h urinary volume is higher and 24-h
urinary osmolarity is also lower in the oldest quintile), or
become resistant to vasopressin with age.
The association between copeptin and UAE has an R-value
of 0.20. This relatively low R-value indicates that other factors
also contribute to UAE. Compared with well acknowledged
modifiable risk factors for UAE, the association between
copeptin and UAE is less strong than that between MAP and
UAE, but of approximately similar strength as BMI,
cholesterol, and glucose (indicated by Figure 3 and the
R-values of these associations). It is furthermore important to
note that the association between copeptin and UAE was
independent of these potential confounders (Table 2).
Copeptin levels are likely to fluctuate according to
changes in volume or plasma osmolarity. This raises the
question whether the observed association will be of
relevance for renal function or albuminuria in the long
run. There is, however, evidence that copeptin levels are
not only dependent on volume status and plasma osmolarity,
but also to a certain extent are genetically determined.
Subjects who have higher thirst and vasopressin threshold
as genetic trait,20–22 could, therefore, be at greater renal risk.
These subjects with higher vasopressin level as a genetic
trait and/or elderly subjects are most likely to profit from
intervention (as drinking water or administration of a
vasopressin-receptor antagonist).
We acknowledge that this study has limitations. First, it is
a cross-sectional epidemiological study. Therefore no certain
causal relationship can be proven. A third factor could
underlie both copeptin level and albuminuria. For instance,
subjects with higher UAE have more risk factors and a greater
extent of subclinical interstitial injury and subsequent
reduction of urine-concentration capacity. The observation
that the association remains significant in the multivariate
regression analysis suggests that this association is indepen-
dent of possible confounding factors. It is, however, possible
that residual confounding remained even in multivariate-
analysis, because it is hard to adjust completely for the
duration or severity of each risk factor for the extent of
tubulointerstitial injury and impairment of water-concentra-
tion capacity. Additional research is needed to point out a
mechanism underlying the observed association. Further-
more, our study consisted of predominantly Caucasian
people, making extrapolation of our results to other
ethnicities difficult.
Strengths of our study, as far as we know, are that, this
is the first study to investigate the association between
endogenous vasopressin and UAE. It confirms the results
obtained with 1-desamino-8-D-arginine-vasopressin admin-
istration in animals and humans. Furthermore, this study
has been performed with a large number of subjects, with
extensive information on a large number of covariates.
In conclusion, our study shows that copeptin (a reliable
substitute for vasopressin) is associated with UAE and micro-
albuminuria, consistent with the hypothesis that vasopressin
induces UAE. If it is true that vasopressin induces
albuminuria, suppressing vasopressin by administration of
a vasopressin-receptor antagonist or simply by drinking
more water might be beneficial for the kidney, especially in
the elderly.
MATERIALS AND METHODS
Study design and population
This study is part of the Prevention of Renal and Vascular End Stage
Disease (PREVEND) Study, a cohort study that investigates the
predictive value of UAE for renal and cardiovascular disease
progression. All inhabitants of the city of Groningen between the
ages 28 and 75 years (85,421 subjects) were asked to provide a
morning urine sample and to fill a short questionnaire on
demographics and cardiovascular history. A total of 40,856 subjects
(47.8%) responded. After exclusion of subjects with insulin-
dependent diabetes mellitus and pregnant women, all others with
urinary albumin concentrationX10mg/l, together with a randomly
selected control group, were invited. Finally, 8592 subjects completed
the total screening program, rendering the actual screening cohort.
Details of this study have been published elsewhere.23,24 For this
study, subjects with a missing copeptin value (n¼ 888, missing
samples), missing 24-h urine collections (n¼ 8), or non-fasting
blood sample (n¼ 103) were excluded, leaving 7593 subjects for
analysis. The PREVEND study was approved by the medical ethics
committee of our institution and was conducted in accordance
with the guidelines of the Declaration of Helsinki Principles.
All participants gave written informed consent.
Measurements and definitions
Participants completed two visits at our outpatient unit. Height and
weight were measured. Information on drug use was provided by
data from community pharmacies. During the first and second visit,
blood pressure was measured on the right arm, in supine position,
every minute for 10 and 8min, respectively, with an automatic
device (Dinamap XL Model 9300; Johnson-Johnson Medical,
Tampa, FL, USA). Two 24-h urine samples were collected after
thorough oral and written instructions on how to perform urine
collection, and fasting blood sample was drawn.
Urinary albumin concentration was determined by nephelometry
(BNII; Dade Behring Diagnostics, Marburg, Germany). Concentrations
of sodium and potassium were measured in urine, and cholesterol
34 Kidney International (2010) 77, 29–36
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and glucose levels were measured in serum using standard methods.
Creatinine concentration was measured using Kodak Ektachem dry
chemistry (Eastman Kodak, Rochester, NY, USA). Copeptin level
was measured by a new sandwich immunoassay (B.R.A.H.M.S. AG,
Hennigsdorf/Berlin, Germany), which was based on the assay
described previously.12
The assay was modified as follows: the capture antibody was
replaced by a murine monoclonal antibody directed to amino acids
137–144 of proAVP. This modification improved the sensitivity of
the assay. The lower detection limit was 0.4 pmol/l and the
functional assay sensitivity (20% inter-assay coefficient of variation)
was less than 1 pmol.25
BMI was calculated as weight in kilograms (kg) divided by
height in square meters (measured to the nearest 0.5 kg and 0.5 cm,
respectively). History of coronary heart disease was defined as self-
reported myocardial infarctions, cardiac operations, percutaneous
transluminal coronary angioplasty, or cerebrovascular accident. This
definition of coronary heart disease would probably misclassify
subjects with unrecognized or silent coronary heart disease.26
Systolic and diastolic blood pressure were measured as mean of
the last two measurements of the two visits. These blood pressure
values were used to calculate mean arterial pressure using the
standard formula 2/3 diastolic blood pressureþ 1/3 systolic blood
pressure. UAE was calculated as the mean of the two 24-h urine
excretions. Included in our definition of diuretic use are all agents
mentioned under C03 of the Anatomical Therapeutic Chemical
(ATC) classification system (low-ceiling diuretics, thiazides, low-
ceiling diuretics, excl thiazides, high-ceiling diuretics, potassium-
sparing agents, diuretics, and potassium-sparing agents in combina-
tion and combinations including these agents). Diabetes was defined
as use of oral antidiabetic medication, a fasting glucose47.0mmol/l
or, in case only a non-fasting sample was available, a non-fasting
plasma glucose 411.1mmol/l). Sodium excretion was used as a
surrogate for sodium intake. Creatinine values were used to calculate
eGFR, using the modification of diet in renal disease formula.27
In early PREVEND papers, creatinine has not been reported as IDMS-
traceable creatinine. To keep reports of creatinine in PREVEND papers
consistent over time, creatinine is always provided as non-IDMS-
traceable values. We have, however, validated creatinine against IDMS
and used this as an additional sensitivity analysis. Microalbuminuria
was defined as an UAE 430mg/24 h. Urinary osmolarity was
calculated as 2*(Urinary sodium concentrationþUrinary potassium
concentration)þUrinary urea concentration. This formula is not
validated in our cohort, but extracted from the literature.28,29,19
Statistical analyses
Analyses were performed with SPSS version 16.0 (SPSS Inc.,
Chicago, IL, USA). Parametric variables are expressed as mean±s.d.,
whereas non-parametric variables are given as median (interquartile
range). Skewed data, such as C-reactive protein (CRP), were
normalized by logarithmic transformation in analyses. A two-sided
Po0.05 was considered to indicate statistical significance.
To visualize associations with copeptin, the study population was
subdivided into quintiles of copeptin concentration. Since males
have a significantly higher copeptin concentration than females,13
when not depicted specifically separately, these quintiles were
stratified for gender. P-values for differences between these quintiles
were obtained using analysis of variance or Kruskal–Wallis test.
Gender-stratified quintiles were also made for BMI, blood
pressure, cholesterol, fasting glucose, and CRP (other modifiable
factors that are known to be associated with increase in UAE in the
non-diabetic population30). This was done to compare the
association between copeptin concentration and UAE with the
association between these other modifiable factors and UAE.
To investigate whether copeptin concentration is associated with
other variables, multiple regression analysis was performed.
Logarithmic transformation of copeptin was applied to fulfill the
requirement of equal distribution of the residuals. This was
performed for the whole group and for males and females separately,
both crude as well as adjusted for age.
To investigate the association between copeptin and UAE,
logarithmic transformation of UAE was also applied and linear
regression was performed. Stepwise, various models were built to
adjust for possible confounding variables for males and females
separately. First the association between log copeptin concentration
and log UAE was investigated crude; second, it was adjusted for age
and gender; third, adjusted for potential cardiovascular confounders
(MAP, BMI, smoking, glucose, cholesterol, CRP, and eGFR); and,
finally, adjusted for medication that could potentially influence both
vasopressin secretion as well as UAE (diuretics and ACEi/ARB). The
same models were used to investigate the association between
urinary osmolarity and UAE in multiple regression analyses.
Interactions between baseline characteristics and log copeptin
concentration were tested in the multivariate model with UAE
being the dependent variable.
Various sensitivity analyses were performed. To test whether use
of diuretics would not only influence copeptin concentration, but
also UAE, the analyses were also performed separately for subjects
with and without diuretic use. Analyses were also performed
stratified for medication influencing the renin–angiotensin system
(ACEi and ARBs, yes/no) and for diabetic status (yes/no). All
analyses were repeated, first, without outliers for copeptin (defined
as a measurement, which falls more than 1.5 times the interquartile
range above the third quartile or below the first quartile31); second,
we repeated the analyses with creatinine values that were IDMS-
traceable. Finally, all analyses were repeated excluding subjects with
420% difference in creatinine excretion in two consecutive 24-h
urine collections as this may indicate incompleteness of urine
collection.
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